[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338204-105":59,"doc-detail-338204-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","plga-astragalus-polysaccharide-nanovaccines-exert-therapeutic-effect-in-colorectal-cancer","PLGA-Astragalus Polysaccharide Nanovaccines Exert Therapeutic Effect in Colorectal Cancer","","Nanovaccine strategy addresses limits of tumor vaccines for solid tumors driven by low immunogenicity. The study develops NP-TCL@APS, combining PLGA nanoparticles carrying colorectal cancer tumor cell lysates (TCL) and Astragalus polysaccharides (APS) to trigger robust innate immunity. Nanoparticles are characterized by electron microscopy and particle-size analysis. In vitro, NP-TCL@APS preferentially enters dendritic cells and promotes activation, enhancing antigen-specific CD8+ T cell responses and inhibiting colorectal tumor growth in mouse models with good biocompatibility.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/plga-astragalus-polysaccharide-nanovaccines-exert-therapeutic-effect-in-colorectal-cancer/338204/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/plga-astragalus-polysaccharide-nanovaccines-exert-therapeutic-effect-in-colorectal-cancer/338204.png","ImageObject",300,407,{"name":92,"@type":93},"Levi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-15","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is NP-TCL@APS and what components does it include?","Question",{"text":112,"@type":113},"NP-TCL@APS is a nanovaccine built with PLGA nanoparticles loaded with colorectal cancer tumor cell lysates (TCL) and Astragalus polysaccharides (APS).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was NP-TCL@APS characterized in the study?",{"text":117,"@type":113},"NP-TCL@APS was identified and characterized using transmission electron microscopy and a Malvern laser particle size analyzer.",{"name":119,"@type":110,"acceptedAnswer":120},"What therapeutic effects were observed in vitro and in mouse models?",{"text":121,"@type":113},"In vitro, NP-TCL@APS preferentially uptakes by dendritic cells and promotes DC activation. In mouse models, co-delivery of TCL and APS enhanced antigen-specific CD8+ T cell responses, suppressed tumor growth, and showed good biocompatibility.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338204,1790798819,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},7971461740909,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","International Journal of Nanomedicine Dovepress  \nopen access to scientific and medical research  \n Open Access Full Text Article ORIGINAL RESEARCH  \nPLGA-Astragalus Polysaccharide Nanovaccines Exert Therapeutic Effect in Colorectal Cancer  \nQian Cao 1 , *, Ruijie Zhou2 , *, Songlin Guo 3 , Kai Meng4 , Xiaojuan Yang 5 , Miao Liu 1 , Bin Ma 6 , Chunxia Su 5 , Xiangguo Duan 2  \n1The First School of Clinical Medicine, Ningxia Medical University, Yinchuan, 750004, People’s Republic of China; 2School of Inspection, Ningxia Medical University, Yinchuan, 750004, People’s Republic of China; 3Institute of Medical Sciences, General Hospital of Ningxia Medical University, Yinchuan, Yinchuan, 750004, People’s Republic of China; 4Traditional Chinese Medicine Hospital of Ningxia Medical University, Yinchuan, 750003, People’s Republic of China; 5School of Basic Medical Sciences, Ningxia Medical University, Yinchuan, 750004, People’s Republic of China; 6Department of Oncology Surgery, the First People’s Hospital of Yinchuan, Yinchuan, 750004, People’s Republic of China  \n*These authors contributed equally to this work  \nCorrespondence: Chunxia Su, School of Basic Medical Sciences, Ningxia Medical University, Yinchuan, 750004, People’s Republic of China, Email [1651085195@qq.com](1651085195@qq.com); Xiangguo Duan, School of Inspection, Ningxia Medical University, Yinchuan, 750004, People’s Republic of China,  \nEmail [2455281549@qq.com](2455281549@qq.com)  \n\n| Background: Tumor vaccines have achieved remarkable progress in treating patients with various tumors in clinical studies. Nevertheless, extensive research has also revealed that tumor vaccines are not up to expectations for the treatment of solid tumors due to their low immunogenicity. Therefore, there is an urgent need to design a tumor vaccine that can stimulate a broad anti-tumor immune response.\u003Cbr>Methods: In this work, we developed a nanovaccine (NP-TCL@APS), which includes nanoparticles loaded with colorectal cancer tumor cell lysates (TCL) and Astragalus polysaccharides (APS) into poly (lactic-co-glycolic acid) to induce a robust innate immune response. The NP-TCL@APS was identified by transmission electron microscopy and Malvern laser particle size analyzer. The killing and immune activation effects of NP-TCL@APS were evaluated in vitro. Finally, safety and anti-tumor efficacy were evaluated in the colorectal cancer tumor-bearing mouse model.\u003Cbr>Results: We found that NP-TCL@APS was preferentially uptaken by DC and further promoted the activation of DC in vitro. Additionally, nanoparticles codelivery ofTCL and APS enhanced the antigen-specific CD8+ T cell response and suppressed the growth of tumors in mouse models with good biocompatibility.\u003Cbr>Conclusion: We successfully prepared a nanovaccine termed NP-TCL@APS, which can promote the maturation of DC and induce strong responses by T lymphocytes to exert anti-tumor effects. The strategy proposed here is promising for generating a tumor vaccine and can be extended to various types of cancers.\u003Cbr>Keywords: colorectal cancer, nanovaccine, PLGA, Astragalus polysaccharide, tumor cell lysates (TCL) |\n| --- |\n| Introduction\u003Cbr>Colorectal cancer (CRC) is one of the most common types of malignant tumors, and has become a major threat to human life. The traditional treatment of malignant tumors is based on surgery, radiotherapy, and chemotherapy. However, many drawbacks induced by these traditional treatments remain challenge including immunosuppression, multiple organic toxicities as well as the risk of tumor recurrence.1 Therefore, it is urgent to develop supplementary anti-tumor strategy with better therapeutic effectiveness and less toxicity in the treatment of cancer.\u003Cbr>Currently, tumor vaccines are considered a promising method for treating tumors. However, the low immunogenicity limits their application. The whole tumor cell lysate (TCL) vaccine includes the entire sequence of mutated tumor antigens is concerned, which significan","cbCaipLmU2bctYZ4","https://ap.wps.com/l/cbCaipLmU2bctYZ4","pdf",27025431,22,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction\n## Limitations of traditional cancer treatments\n## Rationale for tumor vaccines and whole TCL vaccines\n# Publication Information","[{\"question\":\"What is NP-TCL@APS and what components does it include?\",\"answer\":\"NP-TCL@APS is a nanovaccine built with PLGA nanoparticles loaded with colorectal cancer tumor cell lysates (TCL) and Astragalus polysaccharides (APS).\"},{\"question\":\"How was NP-TCL@APS characterized in the study?\",\"answer\":\"NP-TCL@APS was identified and characterized using transmission electron microscopy and a Malvern laser particle size analyzer.\"},{\"question\":\"What therapeutic effects were observed in vitro and in mouse models?\",\"answer\":\"In vitro, NP-TCL@APS preferentially uptakes by dendritic cells and promotes DC activation. In mouse models, co-delivery of TCL and APS enhanced antigen-specific CD8+ T cell responses, suppressed tumor growth, and showed good biocompatibility.\"}]","PLGA-Astragalus Polysaccharide Nanovaccines Exert Therapeutic Effect in Colorectal Cancer | PDF",1790022506,55,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/118bc4445af897af113a56b766f8d918.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7fb674702080520b9863348665dd0d38.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/68f099347d640256617419318ada137e.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e64aa28aa612ca5dcdcaddd1c4c7ba8a.webp",980,1268]